natgillin/translations-raw huggingface dataset:
A valve gearbox as claimed in claim 1, wherein external electrical termination with said valve monitoring sensor (83) is via terminals within said electrical compartment and without said valve (1) having an external electrical junction box, whereby to inhibit tampering with the electrical terminations without removal of said lid. A valve gearbox claimed in claim 1, wherein said mounting (53) is of a non-ferrous material. 
Sklop za upravljanje ventilom s mehaničkim prijenosom prema Zahtjevu 1, gdje se završetak vanjskih električnih veza s navedenim senzorom (83) za praćenje stanja ventila ostvaruje preko terminala koji se nalaze unutar navedenog odjeljka s električnim komponentama i bez toga da navedeni ventil (1) posjeduje vanjsku električnu razvodnu kutiju čime se sprječava neovlašteni pristup i mijenjanje električnih završetaka bez uklanjanja navedenog poklopca.
An apparatus comprising valve gearbox (51) as claimed in any one of claims 1 to 13 fitted to a valve (1). 
Uređaj koji sadrži sklop (51) za upravljanje ventilom s mehaničkim prijenosom prema bilo kojem od Zahtjeva 1 do 13 postavljen na ventil (1).
extraction and elimination of acid gases, such as, for example, carbon dioxide or hydrogen sulphide; 
ekstrahiranja i uklanjanja kiselih plinova, poput, primjerice, ugljičnog dioksida ili sumporovodika;
re-injection into geological formations; 
reinjiciranja u geološke formacije;
detaching the underwater vehicle (1) from the ship or other craft which was towing it; suspending the vehicle (1) to one or more floating buoys (31). 
– odvajanja podvodnog vozila (1) od broda ili drugog plovila koje ga tegli; vješanje vozila (1) na jednu ili više površinskih plutača (31).
installing the first removable module (25) on the underwater vehicle (1); 
instaliranje prvog uklonjivog modula (25) na podvodno vozilo (1);
removing the first removable module (25) from the underwater vehicle (1) and installing the second removable module (25) on the vehicle (1); 
skidanje prvog uklonjivog modula (25) s podvodnog vozila (1) i instaliranje drugog uklonjivog modula (25) na vozilo (1);
An underwater vehicle (1) for transporting fluids such as, for example, natural gas, oil or water, wherein the vehicle (1) comprises at least one containment tube (9) designed for containing the fluid to be transported, and one or more of the following plants: 
Podvodno vozilo (1) za transportiranje fluida poput, primjerice, zemnog plina, sirove nafte ili vode, naznačeno time što vozilo (1) sadrži najmanje jednu cijev za držanje (9), dizajniranu za držanje fluida kojeg treba transportirati, i jedno ili više sljedećih postrojenja:
a plant for stabilizing the stored oil and separating its more volatile fractions and possible gases, liquids, solids or other undesired components dissolved therein; 
postrojenje za stabiliziranje uskladištene sirove nafte i odvajanje njezinih hlapljivijih frakcija i mogućih plinova, tekućina, krutina ili drugi nepoželjnih komponenata otopljenih u njoj;
a plant for separating the acid gases; 
postrojenje za odvajanje kiselih plinova;
a plant for separating predetermined phases or substances from the gas or other fluid to be transported; 
postrojenje za odvajanje zadana faza ili tvari od plina ili drugog fluida kojeg treba transportirati;
a plant for compressing the gases to be stored in the containment tubes (9) and/or air for feeding a circuit of compressed air destined for activating a series of motors, actuations and devices onboard; 
postrojenje za stlačivanje plinova koje treba uskladištiti u cijevima za držanje (9) i/ili zraka za napajanje kruga stlačenog zraka namijenjen za aktiviranje niza motora, aktuatora i uređaja na vozilu;
a plant for re-injecting the fluids (gases or liquids) into geological formations; 
postrojenje za reinjiciranje fluida (plinova ili tekućina) u geološke formacije;
an emergency system; 
sustav za nuždu;
a plant for signalling, telemetry, localization or control of the vehicle (1), or at least its containment tubes (9); 
postrojenje za signaliziranje, telemetriju, lokaliziranje ili upravljanje vozilom (1), ili u najmanju ruku njegovim cijevima za držanje (9);
An apparatus according to any one of the preceding claims, wherein the elongated ferrous object (302) comprises a rope of a hoisting machinery, for example a hoisting machinery in a crane such as a gantry crane or a bridge crane, a ropeway, an elevator, a conveyor in a mine shaft or a ski lift. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da izduženi željezni predmet (302) obuhvaća kabel sustava za podizanje, na primjer sustav za dizanje u dizalici, kao što je portalna dizalica ili mostna dizalica, žičara, dizalo, transportna traka u rudniku ili ski lift.
An arrangement according to claim 10, wherein the arrangement comprises a hoisting machinery in a crane such as a gantry crane or a bridge crane, a ropeway, an elevator, a conveyor in a mine shaft or a ski lift. 
Postrojenje u skladu s patentnim zahtjevom 10, naznačeno time, da uređaj obuhvaća sustav za dizanje u dizalici, kao što je portalna dizalica ili mostna dizalica, žičara, dizalo, transportna traka u rudarskom oknu ili ski lift.
A composition or vaccine for use in a method of inducing an immunogenic or protective response in an animal against one or more avian pathogens, said composition or vaccine comprising a recombinant Gallid herpesvirus 3 (MDV-2) SB-1 strain vector, said vector comprising one or more heterologous polynucleotides coding for and expressing at least one antigen of an avian pathogen, wherein the heterologous polynucleotide encodes the Newcastle Disease Virus protein NDV-F, wherein said method comprises at least one administration of said composition or vaccine. 
Sastav ili cjepivo, naznačen/o time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni sastav ili navedeno cjepivo obuhvaća rekombinantni vektor Gallid herpesvirusa-3 (MDV-2) soja SB-1, gdje navedeni vektor obuhvaća jedan ili više heterolognih polinukleotida koji kodiraju za ekspresiju i eksprimiraju najmanje jednog antigena/jedan antigen ptičjeg patogena, dok heterologni polinukleotid kodira protein virusa Newcastleske bolesti NDV-F, pri čemu spomenuti postupak obuhvaća najmanje jednu primjenu navedenog sastava ili cjepiva.
The composition or vaccine for use according to claim 2, wherein the recombinant HVT vector is vHVT13. 
Sastav ili cjepivo za uporabu prema zahtjevu 2, naznačen/o time, da rekombinantni vektor HVT je vHVT13.
The composition or vaccine for use according to claims 1-2, wherein the NDV-F protein sequence has at least 90% sequence identity to the sequence as set forth in SEQ ID NOs: 2, 9, 50, 52 or 54. 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da sekvenca proteina NDV-F ima najmanje 90% identiteta sekvence prema sekvenci koja je prikazana u SEQ ID NO: 2, 9, 50, 52 ili 54.
The composition or vaccine for use according to claims 1-2, wherein the polynucleotide encoding NDV-F has at least 90% sequence identity to SEQ ID NOs: 1, 8, 49, 51 or 53. 
Sastav ili cjepivo za uporabu prema zahtjevima 1-2, naznačen/o time, da polinukleotid koji kodira NDV-F ima najmanje 90% identiteta sekvence prema SEQ ID NO: 1, 8, 49, 51 ili 53.
The composition or vaccine for use according to any one of claims 1-6, wherein the recombinant Gallid herpesvirus 3 vector comprises a promoter. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-6, naznačen/o time, da rekombinantni vektor Gallid herpesvirusa-3 obuhvaća promotor.
The composition or vaccine for use according to claim 7, wherein the promoter is selected from the group consisting of an immediate early CMV promoter, guinea pig CMV promoter, SV40 promoter, Pseudorabies Virus glycoprotein X promoter, Herpes Simplex Virus-1 alpha 4 promoter, Marek's Disease Virus glycoprotein A (or gC) promoter, Marek's Disease Virus glycoprotein B promoter, Marek's Disease Virus glycoprotein E promoter, Infectious Laryngotracheitis Virus glycoprotein B, Infectious Laryngotracheitis Virus glycoprotein E, Infectious Laryngotracheitis Virus glycoprotein D or Infectious Laryngotracheitis Virus glycoprotein I promoter, and Bovine Herpesvirus 1.1 VP8 promoter. 
Sastav ili cjepivo za uporabu prema zahtjevu 7, naznačen/o time, da je promotor odabran iz skupine koju čine neposredni raniji promotor CMV, promotor zamorca CMV, promotor SV40, promotor glikoproteina X pseudorabies virusa, promotor alfa 4 herpes simpleks virusa-1, promotor glikoproteina A (ili gC) virusa Marekove bolesti, promotor glikoproteina B virusa Marekove bolesti, promotor glikoproteina E virusa Marekove bolesti, promotor glikoproteina B virusa infektivnog laringotraheitisa, promotor glikoproteina E virusa infektivnog laringotraheitisa, promotor glikoproteina D virusa infektivnog laringotraheitisa ili promotor glikoproteina I virusa infektivnog laringotraheitisa, te promotor goveđeg herpesvirusa 1.1 VP8.
The composition or vaccine for use according to any one of claims 1-8, further comprising a pharmaceutically or veterinarily acceptable carrier, excipient, vehicle or adjuvant. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-8, naznačen/o time, da nadalje obuhvaća farmaceutski ili veterinarski prihvatljiv/o nosač, pomoćno sredstvo, prenositelj ili kemijski dodatak.
A recombinant Gallid herpesvirus 3 (MDV-2) SB-1 strain vector comprising a heterologous polynucleotide encoding a Newcastle Disease Virus protein NDV-F, a promoter, and a polyadenylation signal; wherein 
Rekombinantni vektor Gallid herpesvirusa-3 (MDV-2) soja SB-1, naznačen time, da obuhvaća heterologni polinukleotid koji kodira protein virusa Newcastleske bolesti NDV-F, promotor i poliadenilacijski signal; pri čemu:
the heterologous polynucleotide is a wild-type NDV-F VIId polynucleotide, the promoter is a mouse cytomegalovirus IE (mCMV IE) promoter and the polyadenylation signal is an Simian virus 40 (SV40) polyadenylation signal, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region between ORF SORF4 and ORF US10 of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector; or 
heterologni polinukleotid je polinukleotid NDV-F VIId divljeg tipa, promotor je promotor mišjeg citomegalovirusa IE (mCMV IE) i poliadenilacijski signal je poliadenilacijaski signal Simian virusa 40 (SV40), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u područje između ORF SORF4 i ORF US10 od vektora Gallid herpesvirusa-3 (MDV-2) soja SB-1; ili
the heterologous polynucleotide is a codon-optimized NDV-F VIId polynucleotide, the promoter is a SV40 promoter and the polyadenylation signal is SEQ ID NO: 13, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region between ORF UL55 and ORF LORF5 in the unique long (UL) region of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector; or 
heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F VIId, promotor je promotor SV40 i poliadenilacijski signal je SEQ ID NO:13, pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u područje između ORF UL55 i ORF LORF5 u području unikatne duljine (UL) od vektora Gallid herpesvirusa-3 (MDV-2) soja SB-1; ili
the heterologous polynucleotide is a codon-optimized NDV-F VIId polynucleotide, the promoter is a SV40 promoter and the polyadenylation signal is endogenous originating from the glycoprotein C (gC) gene, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region coding for glycoprotein C (UL44) of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector; or 
heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F VIId, promotor je promotor SV40 i poliadenilacijski signal je endogeni koji potječe od gena glikoproteina C (gC), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u područje koje kodira za glikoprotein C (UL44) od vektora Gallid herpesvirusa-3 (MDV-2) soja SB-1; ili
the heterologous polynucleotide is a codon-optimized NDV-F V (CA02 strain) polynucleotide, the promoter is a SV40 promoter and the polyadenylation signal is SEQ ID NO: 13, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region between ORF UL55 and ORF LORF5 in the unique long (UL) region of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector; or 
heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F V (soja CA02), promotor je promotor SV40 i poliadenilacijski signal je SEQ ID NO: 13, pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u područje između ORF UL55 i ORF LORF5 u području unikatne duljine (UL) od vektora Gallid herpesvirusa-3 (MDV-2) soja SB-1; ili
the heterologous polynucleotide is a codon-optimized NDV-F V (CA02 strain) polynucleotide, the promoter is a SV40 promoter and the polyadenylation signal is endogenous originating from the glycoprotein C (gC) gene, further wherein the heterologous polynucleotide encoding NDV-F is inserted into the region coding for glycoprotein C (UL44) of the Gallid herpesvirus 3 (MDV-2) SB-1 strain vector. 
heterologni polinukleotid je kodonski optimizirani polinukleotid NDV-F V (soja CA02), promotor je promotor SV40 i poliadenilacijski signal je endogeni koji potječe od gena glikoproteina C (gC), pri čemu je nadalje heterologni polinukleotid koji kodira NDV-F, umetnut u područje koje kodira za glikoprotein C (UL44) od vektora Gallid herpesvirusa-3 (MDV-2) soja SB-1.
The vector according to claim 10 for use in a method of inducing an immunogenic or protective response in an animal against one or more avian pathogens, wherein said method comprises at least one administration of said composition or vaccine. 
Vektor prema zahtjevu 10, naznačen time, da se upotrebljava u postupku induciranja imunosnog ili zaštitnog odgovora kod životinje protiv jednog ili više ptičjih patogena, pri čemu navedeni postupak obuhvaća najmanje jednu primjenu spomenutog sastava ili cjepiva.
The composition or vaccine for use according to any one of claims 1-9 or the vector for use according to claim 11, further wherein said composition, vaccine or vector is for use in a method of vaccinating an animal, the method comprising at least one administration of the composition, vaccine or vector. 
Sastav ili cjepivo za uporabu prema bilo kojem od zahtjeva 1-9, ili vektor za uporabu prema zahtjevu 11, nadalje naznačeni time, da se navedeni sastav ili vektor, ili navedeno cjepivo, upotrebljavaju u postupku cijepljenja životinje, pri čemu postupak obuhvaća najmanje jednu primjenu sastava, cjepiva ili vektora.
The composition, vaccine or vector for use according to claim 12, wherein the method comprises a prime-boost administration regime. 
Sastav, cjepivo ili vektor za uporabu prema zahtjevu 12, naznačeni time, da postupak obuhvaća prime-boost strategiju primjene.
The composition, vaccine or vector for use according to any one of claims 1 to 9 or 11-13, wherein the animal is avian. 
Sastav, cjepivo ili vektor za uporabu prema bilo kojem od zahtjeva 1 do 9 ili 11 do 13, naznačeni time, da životinja je ptica.
A compound of the general formula (II), 
Spoj opće formule (II),
A process for the preparation of a compound of formula (II) as claimed in claim 3, which comprises: 
Postupak za pripremu spoja formule (II) sukladno patentnom zahtjevu 3, koji sadrži:
Step (i): reacting N-Boc piperazine of formula 1 in presence of acetic acid and aqueous formaldehyde of formula 2 to obtain Mannich adduct; HCHO 2 
Korak (i): reakciju N-Boc piperazina formule 1 uz prisutnost octene kiseline i vodene otopine formaldehida formule 2 da bi se dobio Mannich adukt;
A pharmaceutical composition comprising a compound according to claim 1 and pharmaceutically acceptable excipients. 
Farmaceutski pripravak koji sadrži spoj sukladno patentnom zahtjevu 1 i farmaceutski prihvatljive ekscipijense.
A compound according to claim 3, for use in the treatment of diseases related to 5-HT6 receptor. 
Spoj sukladno patentnom zahtjevu 3, radi liječenja bolesti povezanih s 5-HT6 receptorom.
A pharmaceutical composition comprising a compound according to claim 3 and pharmaceutically acceptable excipients. 
Farmaceutski pripravak koja sadrži spoj sukladno patentnom zahtjevu 3 i farmaceutski prihvatljive ekscipijense.
A compound of formula (I) as claimed in claim 1, for manufacture of a medicament for treatment of a disorder of central nervous system related to or affected by the 5-HT6 receptors. 
Spoj formule (I) sukladno patentnom zahtjevu 1, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT6 receptorima.
A compound of formula (II) as claimed in claim 3, for manufacture of a medicament for treatment of a disorder of central nervous system related to or affected by the 5-HT6 receptors. 
Spoj formule (II) prema patentnom zahtjevu 3, za proizvodnju lijeka za liječenje poremećaja središnjeg živčanog sustava povezanog s ili pogođenog s 5-HT6 receptorima.
Method according to claim 1, characterized in, that the pozzolan is subjected to a pre-classification to separate a fraction with a retention on the sieve 45 microns which is at least 90% and in that the oversized particles are grinded to a fineness with a retention on the sieve 30 microns less than 5% to achieve a strength according to the pozzolanic index ASTM C 618 after 28d days which is > 75 %. 
Postupak prema patentnom zahtjevu 1, naznačen time što se pucolan podvrgava pred-klasifikaciji kako bi se odvojila frakcija s retencijom na situ od 45 mikrona koja je najmanje 90 % i time što se prevelike čestice usitnjavaju do finoće s retencijom na situ od 30 mikrona manje od 5 % kako bi se postigla čvrstoća prema pucolanskom indeksu ASTM C 618 nakon 28 dana koja je > 75 %.
Method according to claim 1, characterized in, that the pozzolan is subjected to a pre-classification to separate a fraction with a retention on the sieve 45 microns which is at least 95% and in that the oversized particles are grinded to a fineness with a retention on the sieve 30 microns which is less than 5%. 
Postupak prema patentnom zahtjevu 1, naznačen time što se pucolan podvrgava pred-klasifikaciji kako bi se odvojila frakcija s retencijom na situ od 45 mikrona koja je najmanje 95 % i time što se prevelike čestice usitnjavaju do finoće s retencijom na situ od 30 mikrona koja je manja od 5 %.
Method according to any of the claims 1 - 4, characterized in, that Portland cement is added in the amount up to 10% by weight to the said pozzolan during or after said processing of the pozzolan. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 - 4, naznačen time što se Portlandski cement dodaje u količini do 10 masenih % u navedeni pucolan tijekom ili nakon navedene obrade pucolana.
is selected from the group consisting of H, C1-C4 alkyl, and -COOH or R1 and R2 taken together with the carbon to which they are attached form a ring selected from a C3-C6 cycloalkyl ring and a 4-6 membered heterocyclic ring containing up to two heteroatoms selected from N, O and S as ring members; 
je odabran iz skupine koja se sastoji od H, C1-C4 alkila, i -COOH ili su R1 i R2 uzeti zajedno s ugljikom na koji su vezani tvore prsten odabran od C3-C6 cikloalkil prstena i 4-6-članog heterocikličnog prstena koji sadrži do dva heteroatoma odabrana od N, O i S kao članove prstena;
X is phenyl, or a 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members; where the phenyl and 5-6 membered heteroaryl are optionally substituted with one or two groups selected from C1-4 alkyl, hydroxy, -CN, F, C1-4 alkoxy, -NH2, -NH(C1-4 alkyl) and -N(C1-4 alkyl)2; 
X je fenil ili 5-6-člani heteroaril prsten koji sadrži 1-3 heteroatoma odabranih od N, O i S kao članove prstena; gdje su fenil i 5-6-člani heteroaril izborno supstituirani jednom ili dvije skupine odabrane od C1-4 alkila, hidroksi, -CN, F, C1-4 alkoksi, -NH2, -NH(C1-4 alkil) i -N(C1-4 alkil)2;
is independently at each occurrence a bond or a straight chain or branched C1-4 alkylene, optionally substituted with NH2, OH, or F; 
je nezavisno u svakom pojavljivanju veza ili ravni lanac ili razgranati C1-4 alkilen, izborno supstituiran s NH2, OH ili F;
Het is a 4-6 membered saturated heterocyclic ring, where the heterocyclic ring contains 1 or 2 heteroatoms selected from N, O and S as ring members and is substituted with oxo and optionally further substituted with Y; 
Het je 4-6-člani zasićeni heterociklični prsten, pri čemu heterociklični prsten sadrži 1 ili 2 heteroatoma odabranih od N, O i S kao članove prstena i supstituiran je s okso i izborno je dalje supstituiran s Y;
and R12 are independently H or C1-4 alkyl optionally substituted by one or two groups selected from OH, NH2 or Q; 
i R12 su nezavisno H ili C1-4 alkil izborno supstituiran jednom ili dvije skupine odabrane od OH, NH2 ili Q;
The compound of claim 1, wherein R1 and R2 together with the carbon to which they are both attached form a cyclopropane ring and R3 is -COOH. 
Spoj prema zahtjevu 1, naznačen time što R1 i R2 zajedno s ugljikom na koji su vezani tvore ciklopropanski prsten i R3 je -COOH.
A pharmaceutical composition comprising a compound of any of the preceding claims and at least one pharmaceutically acceptable excipient. 
Farmaceutski sastav koji sadrži spoj prema bilo kojem od prethodnih zahtjeva i barem jednu farmaceutski prihvatljivu pomoćnu tvar.
A compound according to any of claims 1-10, or a pharmaceutical composition of claim 11 for use in a method to treat a Gram-negative bacterial infection. 
Spoj prema bilo kojem od zahtjeva 1-10, ili farmaceutski sastav prema zahtjevu 11 za uporabu u postupku liječenja Gram-negativne bakterijske infekcije.
The compound or pharmaceutical composition for use according to claim 13, wherein the bacterial infection is nosocomial pneumonia, an intraabdominal infection, or a urinary tract infection caused by a species of Enterobacteriaceae. 
Spoj ili farmaceutski sastav za uporabu prema zahtjevu 12, naznačen time što je bakterijska infekcija nozokomijalna upala pluća, intraabdominalna infekcija ili infekcija urinarnog trakta uzrokovana vrstom enterobakterije.
The compound according to claim 1, wherein the compound of Formula I is a compound selected from: 
Spoj iz zahtjeva 1, pri čemu je spoj: ili njegova farmaceutski prihvatljiva sol.
A compound for use according to claim 17, wherein the avermectin or milbemycin compound is abamectin, dimadectin, doramectin, emamectin, eprinomectin, ivermectin, latidectin, lepimectin, selamectin, milbemectin, milbemycin D, moxidectin, nemadectin, a 5-oxo avermectin or milbemycin derivative, a 5-oxime avermectins or milbemycin derivative, or a combination thereof. 
Spoj za uporabu prema zahtjevu 12, naznačen time, da se spoj primjenjuje u kombinaciji s učinkovitom količinom spoja avermektina ili milbemicina, još poželjnije abamektina, dimadektina, doramektina, emamektina, eprinomektina, ivermektina, latidektina, lepimektina, selamektina, milbemektina, milbemicina D, moksidektina, nemadektina, 5-okso-avermektina ili derivata milbemicina, 5-oksim-avermektina ili derivata milbemicina, ili njihovih kombinacija.
X is phenyl, or a 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S as ring members; where the phenyl and 5-6 membered heteroaryl are optionally substituted with one or two groups selected from C1-4 alkyl, hydroxy, -CN, F, C1-4 alkoxy, -NH2, -NH(C1-4 alkyl) and -N(C1-4alkyl)2; is selected from 
X je fenil ili 5-6-člani heteroaril prsten koji sadrži 1-3 heteroatoma odabranih od N, O i S kao članove prstena; gdje su fenil i 5-6-člani heteroaril izborno supstituirani jednom ili dvije skupine odabrane od C1-4 alkila, hidroksi, -CN, F, C1-4 alkoksi, -NH2, -NH(C1-4 alkil) i -N(C1-4 alkil)2;
The AAV capsid protein of claim 1, wherein the amino acid sequence has at least 99.5% identity to SEQ ID NO: 3. 
Protein kapsida AAV prema patentnom zahtjevu 1, naznačen time, što aminokiselinska kiselina ima identitet najmanje 99,5 %-tno jednak sekvenci SEQ ID NO: 3.